Cardiff Oncology Inc (NASDAQ: CRDF) on Monday, plunged -8.64% from the previous trading day, before settling in for the closing price of $4.28. Within the past 52 weeks, CRDF’s price has moved between $2.01 and $5.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 19.36%. The company achieved an average annual earnings per share of 16.32%. With a float of $60.75 million, this company’s outstanding shares have now reached $66.53 million.
Considering the fact that the conglomerate employs 33 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 58.04%, operating margin of -10876.83%, and the pretax margin is -10201.67%.
Cardiff Oncology Inc (CRDF) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cardiff Oncology Inc is 8.68%, while institutional ownership is 42.08%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 16.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.49% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Cardiff Oncology Inc (CRDF) is currently performing well based on its current performance indicators. A quick ratio of 6.22 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 440.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.93 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Compared to the last year’s volume of 1.19 million, its volume of 1.56 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 54.06%.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 70.62%, which indicates a significant increase from 56.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.26 in the past 14 days, which was higher than the 0.25 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.46, while its 200-day Moving Average is $3.41.
